“Early Detection and Monitoring of Cisplatin-ototoxicity Using Distortion Product Otoacoustic Emissions and Extended Frequency Pure Tone Audiometry in Young Children”
A project submitted in partial fulfilment of the requirements for the degree of
Master of Science
In Human Communication Disorders
Halifax, Nova Scotia
The present study aimed to demonstrate the usefulness of using Distortion product oto-acoustic emissions (DPOAEs) and extended frequency pure tone audiometry (EFPTA) as a tool for the early detection and monitoring of cisplatin-induced ototoxicity in children undergoing chemotherapy treatment. Two children were involved in the study, 13 years old female who received two cisplatin chemotherapy doses (cumulative dose of cisplatin was 180 mg/m²), and 14 years old male who received also two chemotherapy doses (cumulative dose of cisplatin was 150 mg/m²). The measurements used were EFPTA (tested at 2, 4, 6, 8, 10 & 12.5 kHz) and DPOAEs recorded using two different commercially available systems: Bio-logic Au Dx System (frequencies tested: 2, 4, 6, 8 & 10 kHz) and the ILO 92 Oto-dynamic System (frequencies tested: 2, 4 & 6 kHz). Participants were tested at baseline and prior to each next cisplatin infusion. In participant (A), DPOAE obtained by the Bio-logic System showed early signs of ototoxicity even before pure tone audiometric loss occurs. In participant (B), ototoxicity was detected by DPOAE & EFPTA at the same time. The present study showed that EFPTA & DPOAEs are useful techniques for monitoring of cochlear function in children undergoing cisplatin chemotherapy. Most importantly, the present study suggests that DPOAEs may have the potential to predict the earliest stages of cochlear changes due to cisplatin-ototoxicity before changes are noted in EFPTA.